StonvexLoading…
StonvexStonvexStonvexCore line items from ARVN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Q1 2025 2025-03-31 | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 |
|---|---|---|---|---|
Revenue | $15.60M | $188.80M | $46.70M | $20.30M |
Operating Income | $-63.80M | $71.40M | $-188.40M | $-140.90M |
Net Income | $-57.60M | $82.90M | $-191.00M | $-138.00M |
EPS (Diluted) | $-0.90 | $1.14 | $-3.82 | $-2.81 |
Total Assets | $647.50M | $1.00B | $1.58B | $1.60B |
Total Liabilities | $260.70M | $341.00M | $799.90M | $787.13M |
Cash & Equivalents | $87.30M | $81.00M | $108.30M | $255.66M |
Free Cash Flow OCF − CapEx | $-70.50M | $-89.30M | $554.70M | $592.30M |
Shares Outstanding | 64.50M | 73.00M | 53.00M | 52.77M |